You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. High-Power Vertical-Junction Field-Effect Transistors Fabricated on Low-Dislocation-Density GaN by Epitaxial Lift-Off [Phase IIS]

    SBC: Microlink Devices, Inc.            Topic: 1

    In this program, we will develop a breakthrough technology that will enable wafer-scale epitaxial lift-off (ELO) of GaN power device heterostructures from low-dislocation-density bulk GaN substrates. This technology will be used to provide a low-cost vertical junction field effect transistors (VJFETs) with high breakdown voltage (greater than 1,200 V) and high current capability (greater than 100 ...

    SBIR Phase II 2014 Department of EnergyARPA-E
  2. Low Cost, Efficient Microchannel Plasma Ozone System for Point of Use Water Treatment

    SBC: EP Purification, Inc.            Topic: A

    A team at EP Purification has performed research for the development and commercialization of low-cost microchannel plasma reactor modules capable of efficiently producing ozone for water treatment and other environmental applications in a slim form factor and size. The conservation of water resources for human consumption is a growing national priority. Ozone is a unique purification agent as it ...

    SBIR Phase II 2014 Environmental Protection Agency
  3. Mycological Biopolymer as a Replacement for Expanded Plastic Foams

    SBC: Ecovative Design Llc            Topic: B

    Plastics and petroleum-based foams are a conventional solution for the material needs of many industries. Today these non-biodegradable, fossil fuel derived products compose 13 percent of all municipal solid waste streams, as opposed to 1 percent in 1960. This waste stream is associated with a number of environmental concerns, including greenhouse gas generation from incineration, as well as land ...

    SBIR Phase II 2014 Environmental Protection Agency
  4. A Novel Small Molecule Therapeutic for Alcoholic Chronic Pancreatitis

    SBC: Angion Biomedica Corp.            Topic: NIAAA

    DESCRIPTION (provided by applicant): Chronic Pancreatitis (CP) is characterized by continuous or recurrent inflammation of the pancreas that leads to permanent destruction of the pancreas resulting in exocrine and endocrine insufficiency. CP is a common disorder associated with significant morbidity and mortality with an incidence of 8.2 and a prevalence of 27.4 per 100 000 population. The etiolog ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. PRECLINICAL TESTING OF HUMAN GHRELIN AND GROWTH HORMONE FOR SEPSIS IN THE ELDLY

    SBC: THERASOURCE, LLC            Topic: NIA

    DESCRIPTION (provided by applicant): The ultimate goal of our proposal is to develop a novel therapeutic approach that will save lives of aged septic patients. Sepsis is the most common cause of death in the non-cardiac intensive care units (ICU). It is particularly a serious problem in the geriatric population. The elderly (e 65 years of age) accounts for 12% of the US population but 65% of sepsi ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Development, Production and Testing of VLP based Respiratory Syncytial Virus (RSV

    SBC: TechnoVax, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): The goal of this proposal is to develop a safe and efficacious virus-like particle (VLP) based-respiratory syncytial virus (RSV) vaccine to prevent the disease caused by this pathogen. The respiratory illnesses provokedby RSV in infants, children and the elderly are of global economical and public health impact. A recent worldwide estimate [5] indicates that ov ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. A Therapeutic for Radiation Induced Lung Injury

    SBC: Angion Biomedica Corp.            Topic: NIAID

    DESCRIPTION (provided by applicant): Nuclear accidents and terrorism present a serious threat for causing mass-casualty scenarios. In radiation events, many people receive non-uniform whole-body or partial-body irradiation. The risk of exposure to ionizingradiation due to terrorist activities could result in acute injury as well as long-term adverse health effects in thousands of people. The lung ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Large Scale Synthesis of the Next Generation Synthetic Saponin Adjuvant TiterQuil

    SBC: ADJUVANCE TECHNOLOGIES, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Antitumor and anti-infectious disease vaccines require adjuvants in order to obtain optimal immunogenicity and therapeutic and protective efficacy. QS-21 is a natural saponin fraction that significantly out-performs other adjuvants in eliciting productive antibody and T-cell responses. It has remained the adjuvant of choice and has proven it's potency as i ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Topically-delivered Mutation-specific Gene Targeting for Epidermolytic Ichthyosis

    SBC: Exicure, Inc.            Topic: NIAMS

    DESCRIPTION (provided by applicant): AuraSense Therapeutics (AST), along with Northwestern University, is applying a recently developed technology using oligonucleotide-functionalized nanoparticles (called spherical nucleic acids or SNAs) to control protein expression. These easily synthesized nanoparticles can have either DNA or RNA shells, and are less than 50 nm in hydrodynamic diameter. SNA co ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Discovery of inhibitors of the metabolic oncogene 3-phosphoglycerate dehydrogenas

    SBC: Kadmon Corporation, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Many profound metabolic alterations have been described in solid tumors which present attractive therapeutic targets. One recently described metabolic oncogene is 3- phosphoglycerate dehydrogenase (PHGDH), the rate-limiting step in the pathway synthesizing serine and glycine for proteins, lipids, folate and nucleotide metabolism. The PHGDH gene is amplified a ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government